p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.

about

Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.

P2860

Q38997367-2E9BC40C-3104-4480-B719-3032780B4094 Q41708887-0D45819C-4935-4B92-8736-C747F8310AF8

P2860

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.

Item

http://www.wikidata.org/entity/Q39694093

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

p53-independent ibrutinib resp ...... tes efficacy in high-risk CLL.

@en

p53-independent ibrutinib resp ...... tes efficacy in high-risk CLL.

@nl

type

Item

label

p53-independent ibrutinib resp ...... tes efficacy in high-risk CLL.

@en

p53-independent ibrutinib resp ...... tes efficacy in high-risk CLL.

@nl

prefLabel

p53-independent ibrutinib resp ...... tes efficacy in high-risk CLL.

@en

p53-independent ibrutinib resp ...... tes efficacy in high-risk CLL.

@nl

P1476

p53-independent ibrutinib resp ...... tes efficacy in high-risk CLL.

@en

P2093

A Mejia

http://www.w3.org/2001/XMLSchema#string

A Quintas-Cardama

http://www.w3.org/2001/XMLSchema#string

H J Lee

http://www.w3.org/2001/XMLSchema#string

H Ma

http://www.w3.org/2001/XMLSchema#string

L R Pageon

http://www.w3.org/2001/XMLSchema#string

S M Post

http://www.w3.org/2001/XMLSchema#string

X Su

http://www.w3.org/2001/XMLSchema#string

X Zhang

http://www.w3.org/2001/XMLSchema#string

Y Qi

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

TP53 mutation and survival in chronic lymphocytic leukemia.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Postibrutinib outcomes in patients with mantle cell lymphoma.

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

P2888

bcj.2016.41

P304

e434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2016.41

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Miguel Gallardo

Connie A Larsson

Marisa J Hornbaker

P577

2016-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1010584562

http://www.w3.org/2001/XMLSchema#string

P698

27284738

http://www.w3.org/2001/XMLSchema#string

P932

5141356

http://www.w3.org/2001/XMLSchema#string

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.

about

P2860

P2860

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P932